TOP1 and neoplasm: The new hybrid molecule showed a potency superior to both HDAC inhibitor SAHA and Top1 inhibitor Irinotecan, increased antitumor activity and very high tolerability in in vivo human tumor models with respect to SAHA and Topotecan.